PGX ahead of scheduleGood to see PGX-YBG product specifications have been nailed down, the 100L pressure vessel design 100% completed with industry leader Natex, and initial safety and regulatory risk assessments for the plant completed. It looks like they have the product, technological, and regulatory and safety paths nailed down and with that they now expect commissioning of the 100L facility to be completed by the end of Q3. That's only seven months away!
PGX-YBG as an immune booster expected to be available for the market in Q4 of this year. This 100L PGX facllity is not only commercial-scale establishing an important precedent for PGX as it begins to generate commercial revenue but it is the decision point for mass industrialization of PGX. It is a natural time point for partnering for mass adoption. CZO's previously talked about a 40 million dose immune booster plant with a $100 million net present value. Add the potential net present value of a PGX CoQ10 partnership as PGX-YBG/fibrosis also near potential clinical trials. PGX-YBG may also be a Trojan Horse that can hijack macrophages for drug delivery. As reported in November in bold lettering in CZO's news release, "
McMaster University clearly showed that PGX-YBG gets into the macrophage cell. This important finding further supports the potential of YBG to act as a stand-alone and/or a carrier for other bioactives when transported by macrophages cells." Friday's news release:
"Specifications have been standardized and the product is ready to be used for the PGX scale up projects in Edmonton and Austria. Depending on the successful scale up of PGX technology and approval from health authorities, this product could be offered as an immune booster before year end 2024." "Natex Facility, Austria PGX Scale Up 100 Liters Vessel: The project remains on schedule. PGX pressure vessel design is 100% completed. Initial safety and regulatory risk assessment has also been completed. Commissioning is expected to be completed by end of Q3 2024."